Atopic Dermatitis

Supposedly "unbeatable" eczema (atopic dermatitis) can be successfully treated using tofacitinib, suggest findings published in the Journal of the American Academy of Dermatology.

Atopic dermatitis, sometimes referred to as baby eczema, affects more than three million infants in the United States every year. While there are no established preventive measures, researchers have been making strides in coming up with effective treatment strategies.

The American Academy of Dermatology (AAD) recently released new recommendations encouraging physicians to thoroughly inform patients of their options when it comes to dermatologic medications and procedures.

As summer comes to a close and many have already sent their children off to a new year of school, a study in PLOS One suggests that children who have asthma or eczema may face significant challenges fitting in with their peers.

A review article recently examined the evidence (or lack thereof) supporting the use of textiles, vitamin supplements, climatotherapy, probiotics, bleach baths, and other forms of complementary and alternative medicine for the treatment of atopic dermatitis.

Compared with the general population, patients with atopic dermatitis are significantly more susceptible to Staphyloccocus aureus colonization and skin infections.

Patients afflicted with moderate-to- severe eczema have been successfully treated with rheumatoid arthritis drug, tofacitinib citrate.

Anacor Pharmaceuticals recently announced favorable results from two phase 3 pivotal studies for Crisaborole Topical Ointment, 2% (previously AN2728), a non-steroidal topical anti-inflammatory PDE-4 inhibitor for treating children and adults suffering from mild-to-moderate atopic dermatitis.

Researchers have shown there is a connection between personality characteristics and certain dermatological conditions, most notably in psoriasis and atopic dermatitis. Incorporating the information into your practice involves being at least somewhat aware of psychological factors that may contribute to these conditions.

One of the lead characters in the HBO smash hit Game of Thrones has been told by several characters: "You know nothing, Jon Snow." Unfortunately, a similar quote could be used to describe patients with atopic dermatitis (AD). At the very least, the quote could be modified to, "You know very little."

Researchers are investigating whether microbial therapy can be an effective treatment for several skin and allergic conditions.

Topical application of human breast milk has been deemed extremely beneficial for infants with atopic dermatitis.

Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the US food and Drug Administration (FDA) granted Breakthrough Therapy designation to dupilumab, a fully-human monoclonal antibody, to treat adults suffering from moderate to severe atopic dermatitis (AD)who had an insufficient response to or who were not suitable for topical prescription therapy.

Atopic dermatitis is the most common inflammatory pediatric skin disorder, with reported incidences ranging from 10% to 20%. The principles of effect care include fixing the skin barrier, short-circuiting inflammation, decreasing itching, treating infections, and striving for prevention by addressing the triggers.

Session at Pri-Med Southwest focuses on diagnosing and treating atopic dermatitis and other conditions in children.

A defect in a deeper layer of the skin known as the "tight junctions" may play a key role in the development of atopic dermatitis.

Study shows demographic and geographic variability in prevalence, with higher rates among African Americans, city dwellers, and on the East Coast.

Review the recently published results of three studies that looked at atopic dermatitis in clinical practice.

Vaccine that incorporates nanoparticles filled with potent stimulators of the innate immune system proves promising in clinical trials.

Review findings from two recently published studies looking at imaging in atopic dermatitis.